Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial

The authors aimed to evaluate the efficacy and safety of tirofiban, a glycoprotein IIb/IIIa receptor antagonist, in improving functional independence in patients with acute ischaemic stroke following successful endovascular reperfusion. In a multicentre, double-blind, randomized controlled trial involving 1,380 patients, tirofiban was found to significantly increase the likelihood of functional independence at 90 days compared to placebo, although there was no significant difference in the rates of symptomatic intracranial hemorrhage or mortality between the two groups.